Literature DB >> 2719902

Cimetidine-nicoumalone interaction in man: stereochemical considerations.

T S Gill1, K J Hopkins, J Bottomley, S K Gupta, M Rowland.   

Abstract

1. The cimetidine-nicoumalone interaction was studied in five subjects who received a single 10 mg oral dose of racemic nicoumalone alone and 3 days into an oral regimen of cimetidine of 200 mg three times daily and 400 mg at night. 2. The concentrations of R(+)- and S(-)-nicoumalone in plasma were measured using a stereospecific h.p.l.c assay; augmentation of prothrombin time was used as a measure of response. 3. Cimetidine increased the rate (but not extent) of absorption of both R(+)- and S(-)-nicoumalone, and reduced the clearance of R(+)-nicoumalone but not that of the S(-)-enantiomer. 4. Cimetidine increased the anticoagulant response produced by nicoumalone in some but not all subjects, despite a consistent effect on the pharmacokinetics of the oral anti-coagulant. 5. Cimetidine appears to produce its effect by stereoselectively inhibiting the elimination of R(+)-nicoumalone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2719902      PMCID: PMC1379726          DOI: 10.1111/j.1365-2125.1989.tb05395.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Cimetidine interaction with warfarin.

Authors:  D Hetzel; D Birkett; J Miners
Journal:  Lancet       Date:  1979-09-22       Impact factor: 79.321

2.  The stereoselective interaction of warfarin and metronidazole in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1976-08-12       Impact factor: 91.245

3.  High-performance liquid chromatographic method for the simultaneous determination of cimetidine and antipyrine in plasma.

Authors:  A Adedoyin; L Aarons; J B Houston
Journal:  J Chromatogr       Date:  1985-11-29

4.  Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1980-01-03       Impact factor: 91.245

5.  Pharmacokinetics of cimetidine after single doses and during continuous treatment.

Authors:  G Bodemar; B Norlander; A Walan
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

6.  Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

Authors:  R J Lewis; W F Trager; K K Chan; A Breckenridge; M Orme; M Roland; W Schary
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

Review 7.  Cimetidine as an inhibitor of drug metabolism: therapeutic implications and review of the literature.

Authors:  J H Bauman; B J Kimelblatt
Journal:  Drug Intell Clin Pharm       Date:  1982-05

8.  Comparative interaction of cimetidine and ranitidine with racemic warfarin in man.

Authors:  R A O'Reilly
Journal:  Arch Intern Med       Date:  1984-05

9.  Pharmacokinetics of the enantiomers of acenocoumarol in man.

Authors:  J Godbillon; J Richard; A Gerardin; T Meinertz; W Kasper; E Jähnchen
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

10.  Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man.

Authors:  R A O'Reilly
Journal:  Circulation       Date:  1982-01       Impact factor: 29.690

View more
  4 in total

1.  A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol.

Authors:  P Rolan; I J Terpstra; C Clarke; F Mullins; J N Visser
Journal:  Br J Clin Pharmacol       Date:  2003-03       Impact factor: 4.335

Review 2.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Lack of effect of ponsinomycin on the pharmacokinetics of nicoumalone enantiomers.

Authors:  W Couet; B Istin; J P Decourt; I Ingrand; J Girault; J B Fourtillan
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

4.  Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

Authors:  J J Hermans; H H Thijssen
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.